TriangleNCT01177397 · OUTCOME
Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for CC-223
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- ng*h/mL
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Cycle 1 Day -1: pre-dose, 0.5, 1, 1.5, 3, 5, 8, 24 and 48 hours post-dose and Day 15: pre-dose, 0.5, 1, 1.5, 3, 5, and 8 hours post-dose
What was measured
Plasma CC-223 was measured using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.
Analysis population: All treated participants with available pharmacokinetic data in Part A.
Groups in this outcome
Part A: CC-223 7.5 mg
Participants received a single dose of 7.5 mg CC-223 on Day -1, then daily dosing of 7.5 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
Part A: CC-223 15 mg
Participants received a single dose of 15 mg CC-223 on Day -1, then daily dosing of 15 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
Part A: CC-223 30 mg
Participants received a single dose of 30 mg CC-223 on Day -1, then daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
Part A: CC-223 45 mg
Participants received a single dose of 45 mg CC-223 on Day -1, then daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
Part A: CC-223 60 mg
Participants received a single dose of 60 mg CC-223 on Day -1, then daily dosing of 60 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
| Group | Source count |
|---|---|
| Part A: CC-223 7.5 mg | 1 |
| Part A: CC-223 15 mg | 2 |
| Part A: CC-223 30 mg | 8 |
| Part A: CC-223 45 mg | 9 |
| Part A: CC-223 60 mg | 7 |
Reported measurements
Day -1/Day 1
| Group | Source count |
|---|---|
| Part A: CC-223 7.5 mg | 1 |
| Part A: CC-223 15 mg | 2 |
| Part A: CC-223 30 mg | 8 |
| Part A: CC-223 45 mg | 9 |
| Part A: CC-223 60 mg | 7 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part A: CC-223 7.5 mg | 318 | NA | Not reported | Not reported | Insufficient data values to calculate coefficient of variation. |
| Part A: CC-223 15 mg | 347 | 60.2 | Not reported | Not reported | Not reported |
| Part A: CC-223 30 mg | 1204 | 37.8 | Not reported | Not reported | Not reported |
| Part A: CC-223 45 mg | 1493 | 54.3 | Not reported | Not reported | Not reported |
| Part A: CC-223 60 mg | 2080 | 100.8 | Not reported | Not reported | Not reported |
Day 15
| Group | Source count |
|---|---|
| Part A: CC-223 7.5 mg | 1 |
| Part A: CC-223 15 mg | 2 |
| Part A: CC-223 30 mg | 6 |
| Part A: CC-223 45 mg | 6 |
| Part A: CC-223 60 mg | 4 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part A: CC-223 7.5 mg | 179 | NA | Not reported | Not reported | Insufficient data values to calculate coefficient of variation. |
| Part A: CC-223 15 mg | 282 | 100.7 | Not reported | Not reported | Not reported |
| Part A: CC-223 30 mg | 1016 | 39.2 | Not reported | Not reported | Not reported |
| Part A: CC-223 45 mg | 1351 | 45.0 | Not reported | Not reported | Not reported |
| Part A: CC-223 60 mg | 1900 | 93.5 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- comment
- Insufficient data values to calculate coefficient of variation.
- group Id
- OG000
- spread
- NA
- value
- 318
- group Id
- OG001
- spread
- 60.2
- value
- 347
- group Id
- OG002
- spread
- 37.8
- value
- 1204
- group Id
- OG003
- spread
- 54.3
- value
- 1493
- group Id
- OG004
- spread
- 100.8
- value
- 2080
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 8
- group Id
- OG003
- value
- 9
- group Id
- OG004
- value
- 7
- units
- Participants
- title
- Day -1/Day 1
- categories
- measurements
- comment
- Insufficient data values to calculate coefficient of variation.
- group Id
- OG000
- spread
- NA
- value
- 179
- group Id
- OG001
- spread
- 100.7
- value
- 282
- group Id
- OG002
- spread
- 39.2
- value
- 1016
- group Id
- OG003
- spread
- 45.0
- value
- 1351
- group Id
- OG004
- spread
- 93.5
- value
- 1900
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 6
- group Id
- OG003
- value
- 6
- group Id
- OG004
- value
- 4
- units
- Participants
- title
- Day 15
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 2
- group Id
- OG002
- value
- 8
- group Id
- OG003
- value
- 9
- group Id
- OG004
- value
- 7
- units
- Participants
- description
- Plasma CC-223 was measured using validated chiral liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants received a single dose of 7.5 mg CC-223 on Day -1, then daily dosing of 7.5 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
- id
- OG000
- title
- Part A: CC-223 7.5 mg
- description
- Participants received a single dose of 15 mg CC-223 on Day -1, then daily dosing of 15 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
- id
- OG001
- title
- Part A: CC-223 15 mg
- description
- Participants received a single dose of 30 mg CC-223 on Day -1, then daily dosing of 30 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
- id
- OG002
- title
- Part A: CC-223 30 mg
- description
- Participants received a single dose of 45 mg CC-223 on Day -1, then daily dosing of 45 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
- id
- OG003
- title
- Part A: CC-223 45 mg
- description
- Participants received a single dose of 60 mg CC-223 on Day -1, then daily dosing of 60 mg CC-223 for 28 days beginning on Day 1. Participants received subsequent cycles consisting of 28-day continuous dosing without rest between cycles for as long as they derived benefit from treatment as judged by the investigator.
- id
- OG004
- title
- Part A: CC-223 60 mg
- param Type
- GEOMETRIC_MEAN
- population Description
- All treated participants with available pharmacokinetic data in Part A.
- reporting Status
- POSTED
- time Frame
- Cycle 1 Day -1: pre-dose, 0.5, 1, 1.5, 3, 5, 8, 24 and 48 hours post-dose and Day 15: pre-dose, 0.5, 1, 1.5, 3, 5, and 8 hours post-dose
- title
- Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUCt) for CC-223
- type
- PRIMARY
- unit Of Measure
- ng*h/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice